CRL
Charles River Laboratories
Charles River Laboratories historical holders
total: 7
Olstein Capital Management Charles River Laboratories transactions over time
- Total transactions:
- 16
- New positions:
- 2
- Sold out:
- 2
- Added:
- 4
- Reduced:
- 8
- Held since:
- 2016 Q1
- Held for:
- 8 quarters
- Latest activity:
- 2018 Q1
Robert Olstein has been an institutional investor in Charles River Laboratories (CRL) since at least 2013 Q2. According to 2026 Q2 report, Robert Olstein doesn't hold any shares. In our earliest available record from 2013 Q2, Olstein Capital Management held 176,000 shares of CRL. Robert Olstein later completely sold out the position and reinvested in CRL again in 2016 Q1. Since at least 2013 Q2, Olstein Capital Management has made 15 more transactions in this position.
When did Robert Olstein exit their CRL position?
Robert Olstein no longer holds Charles River Laboratories (CRL). They sold off their entire position in 2018 Q1, closing out an investment that began in 2013 Q2.
Has Robert Olstein reinvested in CRL after selling?
Yes, Robert Olstein has shown renewed interest in Charles River Laboratories (CRL). After completely selling their position, they reinitiated an investment in 2016 Q1, demonstrating continued conviction in this ticker.
Estimated cost basis*
- Weighted AVG buy price:
- $79.16
- Weighted AVG sell price:
- $103.37
CRL transactions history by Olstein Capital Management
16 results
| Period |
% of portfolio |
Shares held after* |
Reported price* |
Value* |
% (shares) of activity |
% change to portfolio |
|---|---|---|---|---|---|---|
|
2018 Q1
|
0.00%
|
$109.44
|
-100% (-48,235)
|
|||
|
2017 Q4
|
0.67%
|
$109.44
|
-19.76% (-11,877)
|
|||
|
2017 Q3
|
0.84%
|
$108.02
|
-22.07% (-17,023)
|
|||
|
2017 Q2
|
0.99%
|
$101.15
|
-28.62% (-30,920)
|
|||
|
2017 Q1
|
1.24%
|
$89.95
|
-20.57% (-27,980)
|
|||
|
2016 Q4
|
1.34%
|
$76.19
|
+58.87% (+50,410)
|
|||
|
2016 Q3
|
0.94%
|
$83.34
|
+53.17% (+29,724)
|
|||
|
2016 Q2
|
0.62%
|
$82.43
|
+130.18% (+31,615)
|
|||
|
2016 Q1
|
0.25%
|
$75.93
|
new
|
|||
|
2015 Q1
|
0.00%
|
$63.62
|
-100% (-32,000)
|
|||
|
2014 Q4
|
0.25%
|
$63.62
|
-73.55% (-89,000)
|
|||
|
2014 Q3
|
0.94%
|
$59.74
|
-9.02% (-12,000)
|
|||
|
2014 Q2
|
0.96%
|
$53.52
|
+64.20% (+52,000)
|
|||
|
2014 Q1
|
0.67%
|
$60.35
|
-52.07% (-88,000)
|
|||
|
2013 Q4
|
1.28%
|
$53.04
|
-3.98% (-7,000)
|
|||
|
2013 Q2
|
1.16%
|
$41.03
|
new or own*
|
|||
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.